Advanced Image Guidance Utilized in Liver Surgery

Not Applicable

Completed

• Conditions: Carcinoma, Hepatocellular
• Interventions: Device: Advanced Image Guidance

• Registration Number: NCT01666145
• Lead Sponsor: Wake Forest University Health Sciences

Brief Summary

Advanced Image Guidance for this study was used during laparoscopic microwave ablation surgery to help the surgeon accurately place the ablation needle into the tumor of patients diagnosed with liver cancer.

Detailed Description

Hepatocellular carcinoma (HCC) is diagnosed in over 19,000 Americans annually and responsible for 17,000 deaths. Worldwide, (HCC) is the third leading cause of cancer death. Hepatocellular carcinoma recurs frequently due to its multi-centric nature, which requires repeated treatments and often results in progressively fewer treatment options because of severe underlying liver dysfunction. While surgery offers the best prognosis for such tumors and lesions, only 10-15% of all patients are candidates for removal by surgical means, necessitating the exploration of other treatment options. InnerOptic's AIM Guidance System is designed to alleviate the difficulty in using ultrasound to place a needle. AIM shows the needle and the ultrasound slice in their locations in 3D on a stereo monitor, making the spatial relationship between them obvious. AIM also displays the needle trajectory and where the needle will intersect with the ultrasound image, providing the surgeon with an indication of where the needle will go, if inserted along the needle shaft. AIM can also render an ablation volume guide, providing the surgeon with further confirmation that the needle is placed accurately and providing a volumetric guide regarding the power settings of the ablation.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-05-07
• Study First Submitted QC: 2012-08-14
• Study First Posted: 2012-08-16
• Primary Completion: 2013-09
• Study Completion: 2014-02
• Results First Submitted: 2015-02-03
• Status Verified: 2018-07
• Results First Submitted QC: 2018-07-27
• Results First Posted: 2018-08-27
• Last Update Submitted: 2022-04-20
• Last Update Posted: 2022-04-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Individuals who have hepatocellular carcinoma.
• Individuals who are candidates for microwave ablation surgery.

Read More

Exclusion Criteria

• Individuals who do not have hepatocellular carcinoma.
• Individuals who are not a candidate for laparoscopic microwave ablation surgery.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intraoperative Imaging	Advanced Image Guidance	Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.

Primary Outcome Measures

Name	Time	Method
Successful Insertion of Ablation Antenna Into Target Lesion	Participants will be followed for the duration of hospital stay, an expected average of 2 to 3 days.	Once the ablation antenna has been placed into the target lesion, the success or failure of the attempt will be confirmed with conventional ultrasound alone, in two planes. If the placement is deemed successful, the surgeon will commence the ablation of the tumor. If the placement is deemed insufficient, the probe will be removed and another placement will be attempted using conventional guidance.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM)	Participants will be followed for the duration of hospital stay, an expected average of 2 to 3 days.	A subjective grading scale from which the surgeon will provide the relative ease of lesion targeting using Advanced Image Guidance (AIM) and the guidance system; the scale will be numbered 1-5 with one being significantly difficult and five being significantly easy. The percentage of participants with a score of 5 is reported below.

Trial Locations

Locations (1)

Carolinas Health System; 🇺🇸 Charlotte, North Carolina, United States